One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1182/blood.v130.suppl_1.322.322
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Jun 25, 2021 |
Affiliation: Délégation Paris 7, Policlinico San Matteo Fondazione, Semmelweis University, Osaka City University, Novartis (Switzerland), University of Yamanashi, Royal Brisbane and Women's Hospital, Ziekenhuisnetwerk Antwerpen Stuivenberg, Guy's and St Thomas' NHS Foundation Trust, University of Naples Federico II, Foundation Center, The University of Texas Health Science Center at San Antonio, Saint Agnes Hospital, University of Insubria, Novartis (France), Charité - Universitätsmedizin Berlin, Autonomous University of Barcelona, Hospital Ramos Mejía, Johannes Wesling Klinikum Minden, The University of Texas MD Anderson Cancer Center, University of Florence
Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
